Targeting the Eye: RNA-Based Therapies, Interferences, and Delivery Strategies
Pharmaceutics · 13.10.2025 · 17 (10) · 1326
DOI: 10.3390/pharmaceutics17101326 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 13.10.2025. Verfasst von Mohammed S Abdel-Raziq Hassan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, College of Arts and Sciences, University of Cincinnati, Cincinnati, OH 45221, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, National Eye Institute (NEI) of the National Institutes of Health.
Abstract (Originalsprache)
Recent advances in molecular biology have led to the development of RNA-based therapeutics, offering significant promise for treating various eye diseases. Current RNA therapeutics include RNA aptamers, antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and messenger RNA (mRNA) that can target specific genetic and molecular pathways involved in eye disorders. In addition to their potential in therapy, RNA technologies have also provided tools for mechanistic studies to improve the understanding of eye diseases, expanding the possibilities of RNA-based treatments. Despite the utility of RNA in studying eye disease mechanisms and its potential in disease treatment, only a few RNA-based therapies have been approved for posterior eye diseases. This paper reviews RNA interference and related ocular delivery and posterior eye diseases, focusing on the use of RNA aptamers, siRNA, short hairpin RNA (shRNA), and microRNA (miRNA). Approaches using RNA to advance our understanding of eye diseases and disease treatments, particularly in the posterior segment of the eye, are discussed. It is concluded that RNA therapeutics offer a novel approach to treating a variety of eye diseases by targeting their molecular causes. siRNA, shRNA, miRNA, and ASO can directly silence disease-driving genes, while RNA aptamers bind to specific targets. Although many RNA-based therapies are still in experimental stages, they hold promise for conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), glaucoma, and inherited retinal disorders. Effective delivery methods and long-term safety are key challenges that need to be addressed for these treatments to become widely available.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry, College of Arts and Sciences, University of Cincinnati, Cincinnati, OH 45221, USA.
- Division of Pharmaceutical Sciences, James L Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA.
ORCID-Profile: S Kevin Li
Förderung
- NEI NIH HHS
- National Eye Institute (NEI) of the National Institutes of Health
Zitieren
APA
Hassan, M. S. A., Zhong, C., Hassan, F., & Li, S. K. (2025). Targeting the Eye: RNA-Based Therapies, Interferences, and Delivery Strategies. Pharmaceutics, 17(10), 1326. https://doi.org/10.3390/pharmaceutics17101326
Vancouver
Hassan MSA, Zhong C, Hassan F, Li SK. Targeting the Eye: RNA-Based Therapies, Interferences, and Delivery Strategies. Pharmaceutics. 2025;17(10):1326. doi:10.3390/pharmaceutics17101326
BibTeX
@article{Hassan2025,
author = {Hassan, Mohammed S Abdel-Raziq and Zhong, Cheng and Hassan, Fatma and Li, S Kevin},
title = {Targeting the Eye: RNA-Based Therapies, Interferences, and Delivery Strategies},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {10},
pages = {1326},
doi = {10.3390/pharmaceutics17101326}
}
EUVIMED